ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO186

Low Dose Aspirin Increases 15-Epi-Lipoxin A4 Levels in CKD Patients

Session Information

Category: Nutrition, Inflammation, and Metabolism

  • 1401 Nutrition, Inflammation, Metabolism

Authors

  • Goicoechea, Marian, Hospital General Universitario Gregorio Marañón, Madrid, Spain
  • Sanchez-Nino, Maria Dolores, Fundacion Jimenez Diaz, Madrid, Spain
  • Ortiz, Alberto, Fundacion Jimenez Diaz, Madrid, Spain
  • Garcia de vinuesa, Maria soledad, Hospital General Universitario Gregorio Marañon, Madrid, Spain
  • Quiroga, Borja, Hospital de La Princesa, Madrid, Spain
  • Morales, Enrique, HOSPITAL 12 DE OCTUBRE, MADRID, Spain
  • Fernandez Juarez, Gema, HOSPITAL DE ALCORCON, ALCORCON, Spain
  • De Sequera, Patricia, University Hospital Infanta Leonor, Madrid, MAD, Spain
  • Verdalles, Ursula, Hospital General Universitario Gregorio Marañón, Madrid, Spain
  • Verde, Eduardo, Hospital General Universitario Gregorio Marañon, Madrid, Spain
  • Luno, Jose, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background

Resolution of inflammation is regulated by endogenous lipid mediators, such as lipoxins and their epimers, including 15-epi-lipoxin A4 (15-epi-LXA4). However, there is no information on 15-epi-LXA4 and its in vivo regulation in chronic kidney disease (CKD) patients.

Methods

Study Design: Open label randomized clinical trial.
Setting & Participants: 50 participants with chronic kidney disease (CKD) stage 3 and 4 without prior cardiovascular disease (25 in the aspirin group and 25 in the standard group) followed for 46 months.
Intervention: Aspirin (100 mg/day) or standard treatment.
Aim: To analyze the effect of aspirin on plasma 15-epi-LXA4 levels and inflammatory markers in CKD patients.

Results

Baseline plasma15-epi-LXA4 levels were lower in diabetic (1.22±0.99 ng/ml) than in non-diabetic CKD patients (2.05±1.06 ng/ml, p<0.001) and inversely correlated with glycosylated hemoglobin levels (r=-0.303, p=0.006). In multivariate analysis, diabetes was associated with lower 15-epi-LXA4 levels, adjusted for age, inflammatory markers and renal function (p=0.005). In the whole study population, 15-epi-LXA4 levels tended to increase after twelve months on aspirin (from mean±SD 1.84±1.06 to 2.04±0.75 ng/ml) and decreased in the standard care group (1.60±1.15 to 1.52±0.68 ng/ml, p=0.04). The aspirin effect on 15-epi-LXA4 levels was more striking in diabetic patients, increasing from 0.94±0.70 to 1.93±0.74 ng/ml, p=0.017.

Conclusion

Diabetic patients with CKD have lower circulating 15-epi-LXA4 levels than non-diabetic CKD patients. Low dose aspirin for 12 months increased 15-epi-LXA4 levels, especially in diabetic patients. Given its anti-inflammatory properties, this increase in 15-epi-LXA4 levels may contribute to the beneficial effects of low dose aspirin.

Funding

  • Other NIH Support